Literature DB >> 22643974

Some insights into the binding mechanism of Aurora B kinase gained by molecular dynamics simulation.

Rui Xiong1, Xiao-Mei Cai, Jing Wei, Peng-Yu Ren.   

Abstract

Aurora B kinase is essential in the process of mitosis, and its overexpression has been reported to be associated with a number of solid tumors. We therefore carried out molecular docking, molecular dynamics, and molecular mechanics Poisson-Boltzmann/surface area (MM-PBSA) calculations on several structurally diverse inhibitors (pentacyclic, pyrimidine, quinazoline, and pyrrolopyridine derivatives) and Aurora B kinase to explore the structural and chemical features responsible for the binding recognition mechanism. Molecular simulations reveal that the binding site mainly consists of six binding regions (sites A-F). We have identified that sites B and C are required for optimum binding in Aurora B-inhibitor complexes, sites A and F are needed to improve pharmacokinetic properties, while sites D and E lead to enhanced stability. We verified that hydrogen bonding to the hinge region and hydrophobic contact with the conserved hydrophobic pocket are of critical importance in the systems studied. Specifically, the amino acids Glu171, Phe172, and Ala173 in the hinge region and Leu99, Val107, and Leu223 in the conserved hydrophobic pocket probably account for the high binding affinities of these systems, as shown by hydrogen-bonding analysis and energy decomposition analysis. Hydrophobic contact with Phe172 is also in agreement with experimental data. In addition, the MM-PBSA calculations reveal that the binding of these inhibitors to Aurora B kinase is mainly driven by van der Waals/nonpolar interactions. The findings of this study should help to elucidate the binding pattern of Aurora B inhibitors and aid in the design of novel active ligands.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22643974     DOI: 10.1007/s00894-012-1453-9

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  29 in total

1.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes.

Authors:  Holger Gohlke; Christina Kiel; David A Case
Journal:  J Mol Biol       Date:  2003-07-18       Impact factor: 5.469

2.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

3.  Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts.

Authors:  Bedrick B Gadea; Joan V Ruderman
Journal:  Mol Biol Cell       Date:  2004-12-22       Impact factor: 4.138

4.  SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.

Authors:  Nicola M Heron; Malcolm Anderson; David P Blowers; Jason Breed; Jonathan M Eden; Stephen Green; George B Hill; Trevor Johnson; Frederic H Jung; Helen H J McMiken; Andrew A Mortlock; Andrew D Pannifer; Richard A Pauptit; Jennifer Pink; Nicola J Roberts; Siân Rowsell
Journal:  Bioorg Med Chem Lett       Date:  2005-12-05       Impact factor: 2.823

5.  Crystal structure of aurora-2, an oncogenic serine/threonine kinase.

Authors:  Graham M T Cheetham; Ronald M A Knegtel; Joyce T Coll; Suzanne B Renwick; Lora Swenson; Peter Weber; Judith A Lippke; Douglas A Austen
Journal:  J Biol Chem       Date:  2002-09-16       Impact factor: 5.157

6.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.

Authors:  Jing Yang; Takayuki Ikezoe; Chie Nishioka; Taizo Tasaka; Ayuko Taniguchi; Yoshio Kuwayama; Naoki Komatsu; Kentaro Bandobashi; Kazuto Togitani; H Phillip Koeffler; Hirokuni Taguchi; Akihito Yokoyama
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

7.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Authors:  Mark G Manfredi; Jeffrey A Ecsedy; Kristan A Meetze; Suresh K Balani; Olga Burenkova; Wei Chen; Katherine M Galvin; Kara M Hoar; Jessica J Huck; Patrick J LeRoy; Emily T Ray; Todd B Sells; Bradley Stringer; Stephen G Stroud; Tricia J Vos; Gabriel S Weatherhead; Deborah R Wysong; Mengkun Zhang; Joseph B Bolen; Christopher F Claiborne
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-23       Impact factor: 11.205

8.  Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.

Authors:  Chunli Yan; Zhilong Xiu; Xiaohui Li; Shenmin Li; Ce Hao; Hu Teng
Journal:  Proteins       Date:  2008-10

9.  Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2.

Authors:  Baoguang Zhao; Angela Smallwood; Jingsong Yang; Kristin Koretke; Kelvin Nurse; Amy Calamari; Robert B Kirkpatrick; Zhihong Lai
Journal:  Protein Sci       Date:  2008-07-28       Impact factor: 6.725

10.  Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.

Authors:  Kelly Anderson; Zhihong Lai; Octerloney B McDonald; J Darren Stuart; Eldridge N Nartey; Mary Ann Hardwicke; Ken Newlander; Dashyant Dhanak; Jerry Adams; Denis Patrick; Robert A Copeland; Peter J Tummino; Jingsong Yang
Journal:  Biochem J       Date:  2009-05-13       Impact factor: 3.857

View more
  1 in total

1.  Exploration of the structural requirements of Aurora Kinase B inhibitors by a combined QSAR, modelling and molecular simulation approach.

Authors:  Sajda Ashraf; Kara E Ranaghan; Christopher J Woods; Adrian J Mulholland; Zaheer Ul-Haq
Journal:  Sci Rep       Date:  2021-09-21       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.